Bristol-Myers Squibb Company (FRA:BRM)
Germany · Delayed Price · Currency is EUR | Market Cap | 105.41B -5.9% |
| Revenue (ttm) | 41.05B -0.2% |
| Net Income | 6.01B |
| EPS | 2.95 |
| Shares Out | n/a |
| PE Ratio | 17.54 |
| Forward PE | 9.46 |
| Dividend | 2.14 (4.13%) |
| Ex-Dividend Date | Apr 2, 2026 |
| Volume | 391 |
| Average Volume | 327 |
| Open | 52.34 |
| Previous Close | 52.92 |
| Day's Range | 51.68 - 53.18 |
| 52-Week Range | 36.65 - 55.05 |
| Beta | n/a |
| RSI | 59.09 |
| Earnings Date | Apr 30, 2026 |
About FRA:BRM
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Reblozyl to treat ... [Read more]
News
Swiss industry body says US tariffs on pharmaceuticals will harm patients
U.S. President Donald Trump's 100% tariffs on the pharmaceutical industry threaten global production, supply chains and ultimately will harm patients, Switzerland's pharmaceutical association interph...
Drugmakers face 100% tariff unless they cut prices or produce drugs in US
The Trump administration said on Thursday it will impose 100% tariffs on branded pharmaceuticals imported into the United States unless manufacturers agree to government drug pricing deals or commit ...
Global pharma companies that have publicly announced Trump drug pricing agreements
U.S. President Donald Trump secured agreements with 16 major pharmaceutical companies to bring U.S. prescription drug prices in line with those paid in other developed nations in exchange for three-ye...
Bristol Myers Squibb Evolves and Expands Standing in the Gaap to Advance More Equitable Care in Multiple Myeloma as Program Marks Ten Years
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Myeloma--Bristol Myers Squibb Evolves and Expands Standing in the Gaap to Advance More Equitable Care in Multiple Myeloma as Program Marks Ten Years.
Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ACC--BMS Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos in Adolescents with Symptomatic oHCM.
Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Cobenfy--Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy.
Bristol-Myers Squibb: Dividend/Portfolio Renewal Thesis Remains Promising
Bristol-Myers Squibb's new Opdivo Qvantig injectable delivery is expected to secure additional 20Y patent protection, with their efforts to drive physician adoption before 2028 likely to temper top-li...
Bristol-Myers Squibb: An Attractive High-Yield Stock Amid Market Uncertainty
Bristol-Myers Squibb remains a "Buy," offering a high dividend and free cash flow yield amid recent market pullback. BMY's Growth Portfolio drove 16% YoY net sales growth, offsetting Legacy Portfolio ...
Bristol Myers Squibb Reinforces Leadership in oHCM with New Camzyos (mavacamten) Data at American College of Cardiology Annual Scientific Session & Expo 2026 (ACC.26)
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ACC26--BMS Reinforces Leadership in oHCM with New Camzyos Data at American College of Cardiology Annual Scientific Session & Expo 2026 (ACC.26).
Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab).
Bristol Myers Secures FDA Nod For Opdivo Plus Chemo For Untreated Hodgkin Lymphoma
• Bristol-Myers Squibb shares are experiencing downward pressure. Why is BMY stock retreating?
US FDA approves Bristol Myers Squibb's cancer drug for Hodgkin's lymphoma
The U.S. Food and Drug Administration on Friday approved Bristol Myers Squibb's combination treatment for adults and adolescents aged 12 and older with previously untreated Stage III or ...
Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026.
TrumpRx lists many medicines at prices higher than paid in UK
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those ...
Don't Miss This 14% Yield And This Pharma Value Stock
Trinity Capital offers a 14% yield, trading at a discount with a diversified, largely secured portfolio and steady NII outpacing dividends. Bristol Myers Squibb is executing a portfolio transition, wi...
Virtus Large Cap Growth SMA Q4 2025 Portfolio Review
The Silvant Large Cap Growth SMA returned +2.69% (gross)/+1.94% (net) for the quarter, outperforming the Russell 1000 Growth Index's return of +1.12%. Eli Lilly and Alphabet were among the top stock c...
Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CELMoD--Bristol Myers Squibb Announces Positive Phase 3 Data from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma.
U.S. FDA Approves Bristol Myers Squibb's Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #FDA--U.S. FDA Approves Bristol Myers Squibb's Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis.
February Dividends With 4 Raises: 1.6% Up To 14.5%
Rose's Income Garden portfolio reached an all-time high, with forward yield dipping slightly to 6% as portfolio value increased. Mastercard stands out with a 14.5% dividend raise, attractive valuation...
Bristol Myers Squibb Announces Dividend
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend.
Bristol-Myers Squibb Company (BMY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Bristol-Myers Squibb Company (BMY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
REDMOND, Wash. & PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Patients--SystImmune and BMS Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously-Treat...
NYSE Content Update: Two MSCI Indexes to Begin Trading on NYSE Arca Options
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Feb. 25, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the N...